CTLA4 and neoplasm: Ketogenic diets that significantly lower glucose levels in vivo, when combined with the anti‐CTLA‐4 antibody, markedly retarded tumour progression by decreasing PD‐L1 expression and promoting antitumour immunity pathways.46